The Relationship between Adiponectin and Left Ventricular Mass Index Varies with the Risk of Left Ventricular Hypertrophy

PLoS ONE

Volumn 8, Issue 7, 2013, Pages

  Lee, Yonggu ^a,c   Kim, Bae Keun ^a   Lim, Young Hyo ^a   Kim, Mi Kyung ^b   Choi, Bo Youl ^b   Shin, Jinho ^a  

^a Hanyang University College of Medicine   (South Korea)

^b Hanyang University College of Medicine   (South Korea)

^c The Catholic University of Korea   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; ARTERIAL STIFFNESS; ARTICLE; BODY MASS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIASTOLIC BLOOD PRESSURE; DISEASE SEVERITY; ECHOCARDIOGRAPHY; FEMALE; GLOMERULUS FILTRATION RATE; GLUCOSE BLOOD LEVEL; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HIGH RISK POPULATION; HOMEOSTATIC MODEL ASSESSMENT OF INSULIN RESISTANCE; HUMAN; HYPERTENSION; LOW RISK POPULATION; MAJOR CLINICAL STUDY; MALE; METABOLIC PARAMETERS; OBESITY; PROTEIN BLOOD LEVEL; PULSE WAVE; RISK ASSESSMENT; SYSTOLIC BLOOD PRESSURE; WAIST HIP RATIO;

EID: 84880814667     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0070246     Document Type: Article

References (34)

1. Wiecek A, Adamczak M, Chudek J, (2007) Adiponectin-an adipokine with unique metabolic properties. Nephrol Dial Transplant 22: 981-988.
2. Kadowaki T, Yamauchi T, Kubota N, Hara K, Ueki K, et al. (2006) Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J Clin Invest 116: 1784-1792.
3. Park M, Sweeney G (2012) Direct effects of adipokines on the heart: focus on adiponectin. Heart Fail Rev.
4. Shibata R, Ouchi N, Ito M, Kihara S, Shiojima I, et al. (2004) Adiponectin-mediated modulation of hypertrophic signals in the heart. Nat Med 10: 1384-1389.
5. Paakko T, Ukkola O, Ikaheimo M, Kesaniemi YA, (2010) Plasma adiponectin levels are associated with left ventricular hypertrophy in a random sample of middle-aged subjects. Ann Med 42: 131-137.
6. Ebinc H, Ebinc FA, Ozkurt ZN, Dogru MT, Tulmac M, et al. (2008) Impact of adiponectin on left ventricular mass index in non-complicated obese subjects. Endocr J 55: 523-528.
7. Mitsuhashi H, Yatsuya H, Tamakoshi K, Matsushita K, Otsuka R, et al. (2007) Adiponectin level and left ventricular hypertrophy in Japanese men. Hypertension 49: 1448-1454.
8. Hong SJ, Park CG, Seo HS, Oh DJ, Ro YM, (2004) Associations among plasma adiponectin, hypertension, left ventricular diastolic function and left ventricular mass index. Blood Press 13: 236-242.
9. Adamczak M, Blach A, Kolonko A, Szotowska M, Chudek J, et al. (2011) Plasma adiponectin concentration and left ventricular hypertrophy in kidney transplant patients. Clin Transplant 25: 561-568.
10. Bidulescu A, Liu J, Musani SK, Fox ER, Samdarshi TE, et al. (2011) Association of adiponectin with left ventricular mass in blacks: the Jackson Heart Study. Circ Heart Fail 4: 747-753.
11. Ayerden Ebinc F, Ebinc H, Derici U, Aral A, Aybay C, et al. (2009) The relationship between adiponectin levels and proinflammatory cytokines and left ventricular mass in dialysis patients. J Nephrol 22: 216-223.
12. Komaba H, Igaki N, Goto S, Yokota K, Takemoto T, et al. (2007) Adiponectin is associated with brain natriuretic peptide and left ventricular hypertrophy in hemodialysis patients with type 2 diabetes mellitus. Nephron Clin Pract 107: c103-108.
13. Kistorp C, Faber J, Galatius S, Gustafsson F, Frystyk J, et al. (2005) Plasma adiponectin, body mass index, and mortality in patients with chronic heart failure. Circulation 112: 1756-1762.
14. Tamura T, Furukawa Y, Taniguchi R, Sato Y, Ono K, et al. (2007) Serum adiponectin level as an independent predictor of mortality in patients with congestive heart failure. Circ J 71: 623-630.
15. Shinmura K, (2010) Is adiponectin a bystander or a mediator in heart failure? The tangled thread of a good-natured adipokine in aging and cardiovascular disease. Heart Fail Rev 15: 457-466.
16. Yang YJ, Choi BY, Chun BY, Kweon SS, Lee YH, et al. (2010) Dietary zinc intake is inversely related to subclinical atherosclerosis measured by carotid intima-media thickness. Br J Nutr 104: 1202-1211.
17. Weisell RC, (2002) Body mass index as an indicator of obesity. Asia Pac J Clin Nutr 11Suppl 8: S681-684.
18. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, et al. (2005) Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 18: 1440-1463.
19. Zhang H, Mo X, Hao Y, Huang J, Lu X, et al. (2012) Adiponectin Levels and Risk of Coronary Heart Disease: A Meta-analysis of Prospective Studies. Am J Med Sci.
20. Lu JY, Huang KC, Chang LC, Huang YS, Chi YC, et al. (2008) Adiponectin: a biomarker of obesity-induced insulin resistance in adipose tissue and beyond. J Biomed Sci 15: 565-576.
21. Mondal AK, Das SK, Varma V, Nolen GT, McGehee RE, et al. (2012) Effect of endoplasmic reticulum stress on inflammation and adiponectin regulation in human adipocytes. Metab Syndr Relat Disord 10: 297-306.
22. Amin RH, Mathews ST, Alli A, Leff T, (2010) Endogenously produced adiponectin protects cardiomyocytes from hypertrophy by a PPARgamma-dependent autocrine mechanism. Am J Physiol Heart Circ Physiol 299: H690-698.
23. Wang C, Li L, Zhang ZG, Fan D, Zhu Y, et al. (2010) Globular adiponectin inhibits angiotensin II-induced nuclear factor kappaB activation through AMP-activated protein kinase in cardiac hypertrophy. J Cell Physiol 222: 149-155.
24. Frankel DS, Vasan RS, D'Agostino RB Sr, Benjamin EJ, Levy D, et al. (2009) Resistin, adiponectin, and risk of heart failure the Framingham offspring study. J Am Coll Cardiol 53: 754-762.
25. Lloyd-Jones D, Adams RJ, Brown TM, Carnethon M, Dai S, et al. (2010) Heart disease and stroke statistics-2010 update: a report from the American Heart Association. Circulation 121: e46-e215.
26. Zhou J, Fu M, Qian J, Jin X, Zhong C, et al. (2012) Adiponectin through its biphasic serum level is a useful biomarker during transition from diastolic dysfunction to systolic dysfunction- an experimental study. Lipids Health Dis 11: 106.
27. Thorndike RL (1947) Research problems and techniques. Washington, DC: U.S. Govt. print. off. viii, 163 pp.
28. Liao Y, Xuan W, Zhao J, Bin J, Zhao H, et al. (2010) Antihypertrophic effects of adiponectin on cardiomyocytes are associated with the inhibition of heparin-binding epidermal growth factor signaling. Biochem Biophys Res Commun 393: 519-525.
29. Skurk C, Wittchen F, Suckau L, Witt H, Noutsias M, et al. (2008) Description of a local cardiac adiponectin system and its deregulation in dilated cardiomyopathy. Eur Heart J 29: 1168-1180.
30. Tsukamoto O, Fujita M, Kato M, Yamazaki S, Asano Y, et al. (2009) Natriuretic peptides enhance the production of adiponectin in human adipocytes and in patients with chronic heart failure. J Am Coll Cardiol 53: 2070-2077.
31. Luchner A, Burnett JC Jr, Jougasaki M, Hense HW, Heid IM, et al. (2000) Evaluation of brain natriuretic peptide as marker of left ventricular dysfunction and hypertrophy in the population. J Hypertens 18: 1121-1128.
32. Sung SH, Wu TC, Huang CH, Lin SJ, Chen JW, (2011) Prognostic impact of body mass index in patients undergoing coronary artery bypass surgery. Heart 97: 648-654.
33. Tekes S, Cikim AS, (2007) The association of brain natriuretic peptide and insulin resistance in obesity-related hypertension. J Hum Hypertens 21: 546-550.
34. Siervo M, Ruggiero D, Sorice R, Nutile T, Aversano M, et al. (2010) Angiogenesis and biomarkers of cardiovascular risk in adults with metabolic syndrome. J Intern Med 268: 338-347.